SIDEBAR: Future of PARP Inhibitors in Ovarian Cancer Hangs in Balance

Get Permission

"It’s become clear that the PARP inhibitors in general … are active in this disease, and we are just trying to find out the level of activity and … get to the point hopefully where at least one of these agents will be approved for use” in ovarian and related cancers, commented Jonathan S. Berek, MD, of the Stanford Women’s Cancer Center, Stanford, California.

He noted that shortly before the ASCO Annual Meeting, the manufacturer of olaparib announced that it would not advance the drug into phase III trials. “This actually kind of surprised many of us,” he recalled. “This appears to be an active agent, and we need active agents in this disease.”

The company’s concern stemmed from the lack of a survival benefit in trials thus far, according to Dr. Berek. 

Related Articles

Major Strides Seen in Treatment of Gynecologic Cancers

Research reported at this year’s ASCO Annual Meeting shows major strides in treating ovarian and cervical cancers, suggesting the potential of new agents and adding evidence in areas where optimal management is unclear, according to Jonathan S. Berek, MD, of the Stanford Women’s Cancer Center,...

SIDEBAR: All Eyes on Trials of IV vs IP Chemotherapy for Ovarian Cancer

The positive findings from the NOVEL trial add to the debate about how intravenous (IV) chemotherapy stacks up against intraperitoneal (IP) chemotherapy when treating ovarian cancer and the role of dose-dense approaches in general, according to Jonathan S. Berek, MD, of the Stanford Women’s Cancer...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.